Using Biotechnology to Slow Down Alzheimer's Symptoms
Researchers are optimistic
Despite its poor performance in the GSK clinical trials, Roivant founder and CEO VivekRamaswamy, who is just 32 years old, believed that they could produce useful and meaningful results in their own trials of the drug. That’s because of one exception to the drug’s poor results in the previous clinical trials: when intepirdine was taken in conjunction with donepezil (one of the already established cholinesterase inhibitors), it yielded promising results in slowing loss of cognition and the ability to perform daily tasks.
